PLX4032 and melanoma: resistance, expectations and uncertainty

Expert Rev Anticancer Ther. 2011 Mar;11(3):325-8. doi: 10.1586/era.11.3.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Drug Resistance, Neoplasm / genetics*
  • Humans
  • Indoles / therapeutic use*
  • Melanoma / drug therapy*
  • Melanoma / genetics
  • Mutation
  • Protein Kinase Inhibitors / therapeutic use*
  • Proto-Oncogene Proteins B-raf / genetics
  • Sulfonamides / therapeutic use*
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Indoles
  • Protein Kinase Inhibitors
  • Sulfonamides
  • Vemurafenib
  • BRAF protein, human
  • Proto-Oncogene Proteins B-raf